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ABSTRACT
Objectives This study aims to characterise paediatric 
reports with lamotrigine (LTG) and Stevens-Johnson 
syndrome or toxic epidermal necrolysis (SJS/TEN), and to 
explore whether potential risk factors can be identified.
Design This is a retrospective review of suspected 
adverse drug reaction (ADR) reports. Reported time from 
LTG start to SJS/TEN onset, indication for use and dose 
was explored. To identify potential risk groups, report 
features (eg, ages, patient sex, co-reported drugs) for LTG 
and SJS/TEN were contrasted with two reference groups in 
the same database, using shrinkage logOR.
Setting Reports were retrieved from VigiBase, the 
WHO global database of individual case safety reports, in 
January 2015.
Patients Data for patients aged ≤17 years old were 
extracted.
Results There were 486 reports of SJS/TEN in LTG-
treated paediatric patients. Ninety-seven per cent of the 
cases with complete information on time to onset of SJS/
TEN occurred within 8 weeks of initiation of LTG therapy. 
The median time to onset was 15 days (IQR: 10–22 days). 
The proportion of SJS/TEN with LTG and valproic acid (VPA) 
co-reporting was significantly more than non-cutaneous 
ADRs (43% vs 19%, (logOR: 1.60 (99% CI: 1.33 to 1.84)).
Conclusions The results suggest that VPA co-medication 
with LTG therapy is a risk factor for SJS/TEN in the 
paediatric population. Although this relationship has been 
identified from individual case reports, this is the first 
supportive study from a large compilation of cases. SJS/
TEN risk is highest in first 8 weeks of treatment with LTG in 
children and clinicians should be aware of this risk during 
this period.
InTRODuCTIOn
Stevens-Johnson syndrome (SJS) and toxic 
epidermal necrolysis (TEN) are acute 
mucocutaneous reactions characterised by 
generalised blistering, painful, target-like 
lesions on bright erythema. Patients typically 
present with prodromal symptoms, fever 
and severe mucositis.1 SJS and TEN belong 
to the same spectrum of disease with similar 
aetiological origin. TEN is the more severe 
of the two and is characterised by detached 
or detachable skin of >30% of the total body 
surface area. SJS affects <10% of the body 
surface area, while SJS/TEN overlap involves 
10%–30% of the body surface area.2 A popu-
lation-based study in Germany reported an 
incidence of 1.89 cases of SJS and TEN per 
million persons per year.3 Medicines are a 
common cause of SJS/TEN4 with a highest 
risk of onset within the first 8 weeks of treat-
ment.5 Mortality rates at 6 weeks have been 
reported to be between 7.5% and 23%.6 7
What is already known on this topic?
 ► Lamotrigine is a common cause of Stevens-
Johnson syndrome and toxic epidermal necrolysis 
in paediatrics.
 ► The risk for Stevens-Johnson syndrome and toxic 
epidermal necrolysis from co-medication with 
lamotrigine and valproic acid has been described in 
individual case reports.
What this study hopes to add?
 ► This study presents a large dataset of globally 
collected reports on Stevens-Johnson syndrome/
toxic epidermal necrolysis and lamotrigine in 
paediatrics. The results strengthen previous findings.
 ► Stevens-Johnson syndrome/toxic epidermal 
necrolysis is most likely to occur in the first 8 weeks 
of lamotrigine treatment.
 ► Valproic acid and lamotrigine co-medication is a 
possible risk factor for Stevens-Johnson syndrome/
toxic epidermal necrolysis in children.
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The pathogenesis is not yet fully elucidated. However, 
both immunological and genetic factors are involved. 
Unmodified drugs or endogenously modified human 
leucocyte antigen (HLA)-bound drugs or their metabo-
lites are presented to T cells to trigger immune response.8 
Apoptotic keratinocyte death occurs via several pathways, 
for example, the ligation of Fas on keratinocyte by its 
ligand FasL on cytotoxic T cells or keratinocytes and the 
release of granulysin and other cytokines9 Blister fluids 
in TEN has been shown to contain large numbers of 
T lymphocytes, particularly CD8+ lymphocytes, which 
exhibit drug specific cytotoxicity.10
The rarity of SJS and TEN limits the practicability of 
large studies, particularly when investigating subpop-
ulations and individual drugs. The highest number of 
paediatric cases so far published in the literature involved 
80 patients.7 11 Sulphonamides and antiepileptic drugs 
are the drugs most frequently suspected for causing SJS/
TEN.12 This study aims to characterise paediatric reports 
of cases of lamotrigine (LTG) associated with SJS/TEN 
from a large database of spontaneous reports and to 
explore whether potential risk factors can be identified 
and further analysed.
MeThOD
Data source and population
A retrospective review of suspected adverse drug reaction 
(ADR) reports for the paediatric population with SJS or 
TEN following LTG treatment.
VigiBase
Individual case safety reports (ICSRs) of suspected 
ADRs from national pharmacovigilance centres world-
wide are received by the Uppsala Monitoring Centre 
(UMC), WHO Collaborating Centre for International 
Drug Monitoring.13 In January 2015, about 120 countries 
participated in the WHO Programme for International 
Drug Monitoring and over 10 million individual reports 
had been submitted to VigiBase since its inception in 
1968. These reports are stored in VigiBase, the WHO 
global database of ICSRs. The completeness and quality 
of information on the reports varies and the likelihood 
that the suspected adverse reaction is drug related is not 
the same for all cases. The ADRs are coded by the source 
countries either by using the WHO Adverse Reaction 
Terminology (WHO-ART) or the Medical Dictionary for 
Regulatory Activities (MedDRA).14
Inclusion and exclusion of data
A VigiBase search from inception to 1January 2015 was 
performed. An automatic duplicate detection algorithm 
was applied to exclude duplicate reports.15 16 Only reports 
on paediatric ages were retrieved, defined as patients 
aged ≤17 years old and further classified as neonates 
(0–27 days), infants (28 days to 23 months), children 
(2–11 years) and adolescents (12–17 years).
The primary dataset consisted of ICSRs with the 
WHODrug dictionary preferred base ‘lamotrigine’, 
noted by the reporter as the suspected or interacting 
drug, and reported with the MedDRA preferred terms 
(PT),14 ‘Stevens-Johnson syndrome’ or ‘toxic epidermal 
necrolysis’. SJS/TEN overlap, however, is not a separate 
MedDRA listed PT and is reported either as SJS or as 
TEN.
The individual reports in the primary dataset were 
manually screened for duplicate reports and negative 
time to onset (TTO). Reports with a negative TTO, 
in which SJS/TEN occurred before LTG treatment 
was commenced, were excluded. Manually identified 
duplicates were verified by a second researcher before 
exclusion.
Analysis
Overall data
To identify potential risk groups, we contrasted report 
features for the paediatric population treated with 
LTG and experiencing SJS/TEN with two reference 
groups. The analysed features were as follows: age 
groups (defined earlier), patient sex, co-reported type 
of drugs (denoted suspected, interacting or concom-
itant), co-reported type of ADRs, reporting country/
geographical region and whether or not the cases were 
reported with fatal outcome.
The reference groups were as follows:
 ► Reports of LTG (suspected or interacting) recorded 
with any ADRs, except cutaneous ADRs.
 ► Reports with SJS/TEN with any suspected or 
interacting drug, except LTG.
The exclusion of cutaneous reports for reference 
group A was applied to avoid cases, overlapping with 
SJS/TEN, such as with erythema multiforme. Reports 
with cutaneous ADRs were defined with the MedDRA 
system organ class ‘Skin and subcutaneous tissue 
disorders’. The disproportionality measure, OR, is 
used by UMC in its shrinkage version.17 Shrinkage 
logORs were determined within vigiPoint. This is an 
analytic tool developed by the UMC that compares 
reported features for a defined set of reports with 
a reference set to identify key features in data. 
Shrinkage minimises the risk of identifying false asso-
ciations in large-scale pattern discovery.17 The relative 
frequencies of reported features for LTG associated 
with SJS/TEN were contrasted to the reference data-
sets defined above, using ORs with adaptive statistical 
shrinkage. Significant key features were defined as 
those with logOR005>0.5 or logOR995<−0.5, repre-
senting the lower limit or the upper limit of the 99% 
CI. Key features were defined as those features for 
the LTG and SJS/TEN dataset that were significantly 
different from both reference groups (A and B), with 
the exception of cutaneous reactions where compar-
ison was only relevant to reference group B (since 
cutaneous reactions had been excluded in reference 
group A).
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Time to onset
Only reports with complete dates for start of LTG and 
onset of SJS/TEN were included in the TTO analysis. 
Reports with negative TTOs and those with estimated 
dates were excluded from this analysis. The number of 
days from start of LTG to onset of SJS/TEN was calcu-
lated. To investigate whether the TTO for reports with 
LTG and SJS/TEN corresponded to other antiepileptic 
agents known to cause these serious skin reactions, we 
also calculated the TTO for carbamazepine (CBZ) and 
phenobarbital (PBT). Log-rank test of the survival distri-
bution SJS/TEN TTO with LTG indication and patients’ 
age was carried out using the Kaplan-Meier survival anal-
ysis method.
Dose
For children<13 years old, the dose of LTG (mg/kg/day) 
for each report was determined by dividing the daily dose 
(mg) at the TTO of SJS/TEN by body weight (kg). For 
those between 13 and 17 years old, daily LTG dose (mg/
day) was determined. Dosing data from all reports were 
summarised as median and IQR.
ReSulTS
After automatic duplicate exclusion, we identified 500 
paediatric cases of SJS/TEN where LTG was reported 
as suspected between 23 March 1994 (shortly after LTG 
approval in Europe) and 1 January 2015. Fourteen of 
these, including 12 duplicates identified after manual 
screening and 2 with unlikely attribution (negative 
TTO), were further excluded. The remaining 486 cases 
originating from 40 countries were eligible for inclusion. 
The identified key features in comparison with both 
reference groups are described in table 1.
LTG was co-reported with VPA in 207 (207/486, 43%) 
of the SJS/TEN cases and administered alone in 158 of 
the SJS/TEN cases (158/486, 33%), while 121 (121/486, 
25%) of the cases co-reported LTG with other drugs. 
There was a significantly higher proportion of patients 
with SJS/TEN receiving LTG with VPA than the propor-
tion of patients with non-cutaneous ADRs receiving both 
drugs (493/2609, 19%) (logOR: 1.60 (1.33,1.84)). Simi-
larly, a significantly higher proportion of patients with 
SJS/TEN received LTG with VPA than other drugs with 
VPA (181/4349, 4%) (logOR: 3.63 (3.37,3.88)).
The median age for all patients was 12 years (IQR: 8–15 
years). Compared with non-cutaneous ADRs, cases of SJS/
TEN associated with LTG were rarely reported in infancy, 
similar in children and markedly higher in adolescence 
(figure 1). The proportion of SJS/TEN reports in adoles-
cence was also significantly higher in patients receiving 
LTG than those without LTG. There were more female 
SJS/TEN cases (277/482, 57.5%) than male (205/482, 
42.5%). This pattern deviated from the two reference 
groups, but was not significantly different according to 
the statistical thresholds used in this study (table 1). A 
total of 15 cases of fatality (15/486, 3%) and 25 cases 
(25/486, 5%) of recovery with sequelae were reported.
One hundred and ninety reports of SJS/TEN did not 
document the indication for LTG treatment. LTG was 
prescribed for the treatment of epilepsy in 69% (203 
cases) of the 296 cases with known indication; 60% of 
these cases were children and 38% were adolescents. 
Use for bipolar disorders and other forms of affective 
or behavioural disorders accounted for 31% (93 cases) 
of known indications. Fourteen per cent (13/93) of the 
cases receiving LTG for mood or behavioural disorders 
received concurrent VPA treatment compared with 54% 
(109/203) of the known cases of epilepsy receiving both 
drugs. Three quarter of the cases with affective disorders 
were adolescents and 25% were children.
Forty-eight per cent (232 cases) of the SJS/TEN reports 
with LTG provided sufficient information to determine 
the TTO of SJS/TEN (figure 2). In 97%, SJS/TEN 
occurred within 8 weeks of initiation of LTG therapy. 
Three hundred and forty-two and 138 case reports of SJS/
TEN with CBZ and PBT respectively provided informa-
tion on the TTO and 95% and 96% of cases respectively 
occurred within 8 weeks. The median number of days 
between exposure to the drugs and the onset of SJS/
TEN was similar for all three drugs (LTG and SJS/TEN 
has a median TTO of 15 days (IQR: 10–22 days), CBZ 
and PBT were 14 days (IQR: 10–18 days) and 15 days 
(IQR: 10–22 days) respectively). The log-rank test of the 
survival distribution of SJS/TEN did not show any signif-
icant difference in the TTO between patients receiving 
LTG for epilepsy and mood disorders (p=0.09). Similarly, 
there was no significant difference in TTO between chil-
dren and adolescents (p=0.90).
Ninety-seven case reports (20%) of SJS/TEN with 
LTG provided adequate information on LTG dosing, of 
which 38 patients received concomitant VPA medication. 
The median dose of LTG among children without VPA 
was 1.5 mg/kg (IQR: 1.1–2.8), while the median LTG 
dose with VPA was 1.4 mg/kg (IQR: 0.8–2.2). Among 
adolescents (13–17 years old) without concomitant 
VPA medication, the median LTG dose was 100 mg/day 
(IQR: 50–150), while the median LTG dose with VPA was 
50 mg/day (IQR: 25–125).
DISCuSSIOn
This is the largest review of drug-associated SJS/TEN in 
paediatric patients based on a worldwide spontaneous 
reporting system, and therefore offers an opportunity to 
explore the effect of co-medication in this group. The 
study suggests that VPA co-medication increases the risk 
of SJS/TEN in paediatric patients receiving LTG. The 
proportion of reports of SJS/TEN associated with LTG 
and VPA was significantly higher than that of non-cuta-
neous ADRs. This is in keeping with a study in adults in 
which 74% and 64% of adults who developed SJS or TEN, 
respectively, received VPA co-medication with LTG.18 In 
concordance with an earlier multicentre European study, 
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SJS/TEN occurred mostly during the first 8 weeks of LTG 
exposure.5
LTG and VPA are very frequently co-prescribed for 
epilepsy because of their synergistic effect.19 The syner-
gism between both drugs in patients with mood disorders 
has not been evaluated. As a result of its inhibitory effect 
on hepatic glucuronidation, VPA co-medication reduces 
LTG metabolism and plasma levels. In order to mini-
mise the risk of ADRs due to high drug levels, lower 
initial and maintenance doses of LTG are recommended 
when prescribed with VPA.20 The effect of low dose or 
slow escalation of LTG on the risk of either SJS or TEN, 
when prescribed with VPA, could not be established in 
this study because dose data are limited. However, a lower 
median LTG dose was observed for children and adoles-
cents receiving co-medication with VPA in a small subset 
of data in this study.
More than a quarter of the children and adolescents 
with SJS/TEN with recorded indication for use received 
LTG for affective and behavioural disorders. LTG is 
however not licensed for these conditions in children 
and adolescents,21 which means that these population of 
patients were treated without support from controlled 
randomised studies. Therefore, a careful risk–benefit 
assessment for the individual needs to be established 
before using LTG in this population.
limitations
The likelihood that the suspected adverse reaction is 
drug related is not the same for all cases (see online Supple-
mentary material). As previously mentioned, the effect 
of LTG dosing on SJS/TEN has not been determined 
and this could not be done in this study as a result of 
the marked heterogeneity in the reporting methods, as 
well as inadequate dosing information in several reports 
on VigiBase. Reporters were of a varied background, 
including doctors, pharmacists and consumers, and the 
reports varied in details. Furthermore, recording of TTO 
can vary, as some reporters might specify reaction onset 
as the date when the first symptoms started and others as 
the date of diagnosis.22 The list of co-medications in the 
reports may have also been incomplete. Although there 
is no baseline utilisation data to estimate the relative risk 
of SJS/TEN with the drugs, we have identified risks by 
using specific datasets in the database as comparators.
It is not impossible that cases of erythema multiforme 
and other forms of skin rash have been mispresented 
as SJS, particularly in the older reports.23 However, we 
consider the influence from these limitations on the 
core analysis to be marginal, since the study focused on 
comparing report features for LTG and SJS/TEN with two 
reference groups which were subject to the same limita-
tions. The number of fatal cases or long-term sequelae 
from SJS/TEN following LTG treatment was low possibly 
because late sequelae may have been missed, as follow-up 
was often not reported for the cases.
Conclusions
LTG co-medication with VPA is a possible risk factor for 
SJS/TEN, and these risks are generally restricted to the 
first 8 weeks of treatment with LTG. A cohort study is 
required to further establish this risk. Clinicians should 
be aware of these, and parents and children should be 
counselled accordingly.
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Figure 1 Percentage age distribution of lamotrigine-treated 
population who experienced Stevens-Johnson syndrome/
toxic epidermal necrolysis (cases), patients receiving 
lamotrigine who experienced non-cutaneous adverse drug 
reactions (reference A) and experienced Stevens-Johnson 
syndrome/toxic epidermal necrolysis after other drugs 
(reference B). Many of the reports for ages <1 year old 
concern in utero exposure and congenital anomalies.
Figure 2 Time to onset of Stevens-Johnson 
syndrome (SJS) and toxic epidermal necrolysis (TEN) with 
lamotrigine.
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